• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

    5/9/22 4:08:30 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    SC 13G/A 1 kc001_sc13ga.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     SCHEDULE 13G

    (Rule 13d-102)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 1)*

     

    SciSparc, Ltd.

    (Name of Issuer)

     

    Ordinary Shares, NIS 2.00 par value

    (Title of Class of Securities)

     

    88339A 203

    (CUSIP Number)

     

    March 25, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 88339A 203

     

      1.     

    Names of Reporting Persons

     

    Robert J Eide Pension Plan

     

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ¨        (b)  ¨

     

     

      3.  

    SEC Use Only

     

     

      4.  

    Citizenship or Place of Organization

     

    New York

     

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

     

      5.     

    Sole Voting Power

     

    198,122*

     

      6.  

    Shared Voting Power

     

    0

     

      7.  

    Sole Dispositive Power

     

    198,122*

     

      8.  

    Shared Dispositive Power

     

    0

     

      9.    

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    198,122*

     

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    x

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    6.4%

     

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

     

    *Consists of 198,122 of the Issuer’s Ordinary Shares. Robert Eide is the trustee and sole beneficiary of Robert J Eide Pension Plan. In addition, the Reporting Persons own 92,432 Ordinary Shares issuable upon the exercise of warrants, which are not exercisable due to a beneficial ownership limitation of 4.99% of the Issuer’s issued and outstanding Ordinary Shares.

     

     

     

     

    CUSIP No. 88339A 203

     

      1.     

    Names of Reporting Persons

     

    Robert Eide

     

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ¨        (b)  ¨

     

     

      3.  

    SEC Use Only

     

     

      4.  

    Citizenship or Place of Organization

     

    United States

     

    Number of

    Shares

    Beneficially

    Owned By

    Each

    Reporting

    Person

    With:

     

      5.     

    Sole Voting Power

     

    198,122*

     

      6.  

    Shared Voting Power

     

    0

     

      7.  

    Sole Dispositive Power

     

    198,122*

     

      8.  

    Shared Dispositive Power

     

    0

     

      9.    

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    198,122*

     

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     x

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    6.4%

     

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

     

    *Consists of 198,122 of the Issuer’s Ordinary Shares. Robert Eide is the trustee and sole beneficiary of Robert J Eide Pension Plan. In addition, the Reporting Persons own 92,432 Ordinary Shares issuable upon the exercise of warrants, which are not exercisable due to a beneficial ownership limitation of 4.99% of the Issuer’s issued and outstanding Ordinary Shares.

     

     

     

     

    Item 1(a). Name of Issuer

     

    SciSparc, Ltd., an Israeli corporation (the “Issuer”)

     

    Item 1(b). Address of the Issuer’s Principal Executive Offices

     

    20 Raul Wallenberg Street, Tower A

    Tel Aviv 6971916, Israel 

     

    Item 2(a). Names of Persons Filing

     

    Robert J Eide Pension Plan and Robert J. Eide (collectively, the “Reporting Persons”)

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:

     

    810 7th Avenue #18, New York, NY 10019

     

    Item 2(c). Citizenship

     

    Robert J Eide Pension Plan is a pension plan formed in New York and Robert Eide is a United States citizen.

     

    Item 2(d). Title of Class of Securities

     

    Ordinary Shares, par value NIS 2.00 (the “Ordinary Shares”).

     

    Item 2(e). CUSIP Number

     

    88339A203

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      ¨   (a) Broker or Dealer registered under Section 15 of the Exchange Act.
         
      ¨   (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
         
      ¨   (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
      ¨   (d) Investment company registered under Section 8 of the Investment Company Act.
         
      ¨   (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
         
      ¨   (f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
         
      ¨   (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
           
      ¨   (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

     

     

     

      ¨   (i) A Church Plan that is excluded from the definition of an investment company under Section 3 (c)(14) of the Investment Company Act.
         
      ¨   (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
         
      x   Not applicable

     

     

    Item 4.

    Ownership

      

    The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

    The percentage set forth on Row (11) of the cover page for the Reporting Person is based on 3,091,740 Ordinary Shares outstanding as of December 31, 2021, as represented in the Issuer’s 20-F filed under Section 13 or 15 (d) of the Securities Exchange Act of 1934 on April 28, 2022 with the Securities and Exchange Commission.

     

    Robert J Eide Pension Plan is the record holder of the shares reported herein. Robert Eide is the trustee and sole beneficiary of Robert J Eide Pension Plan.

     

    The Reporting Persons beneficially own an aggregate of 198,122 Ordinary Shares. In addition, the Reporting Persons own 92,432 Ordinary Shares issuable upon the exercise of warrants, which are not exercisable due to a beneficial ownership limitation of 4.99% of the Issuer’s issued and outstanding Ordinary Shares.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below we certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    DATE: May 9, 2022

     

      ROBERT J EIDE PENSION PLAN
       
      By: /s/ Robert Eide
      Name: Robert Eide
      Title: Trustee
         
        /s/ Robert Eide
        Robert Eide

     

     

     

    Get the next $SPRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    SEC Filings

    See more
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 7:11:58 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by SciSparc Ltd.

      S-8 - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 8:56:08 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/25/25 8:19:42 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

      TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psych

      4/25/25 7:59:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office ("KIPO"). The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of cocaine addiction. The patent is based on preclinical trial results led by P

      3/10/25 7:45:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Mu

      3/10/25 7:27:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Financials

    Live finance-specific insights

    See more
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    See more
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care